2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
Published 3 years ago • 167 plays • Length 11:23Download video MP4
Download video MP3
Similar videos
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
7:24
2020 ttf egfr session qa panel does progression always occur on osimertinib (tagrisso)?
-
7:09
2020 ttf egfr session - qa panel preferred chemo regimen when targeted therapy options are exhausted
-
16:48
2020 ttf egfr breakout - weiss choice of frontline egfr therapies
-
1:39
2020 ttf egfr session qa panel what is the difference between c797s and c797x
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
19:31
2020 ttf am session - janne - insights into acquired resistance: the role of repeat biopsies
-
3:07
third generation egfr tkis for acquired resistance
-
24:36
treatment options for egfr t790m negative acquired resistance
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
3:35
grace targeted therapies lung cancer 2021 - current treatment options for egfr fusions e.g. rad 51
-
2:10
slcvl raez #17 treatment options for acquired resistance to egfr tkis: t790m-negative disease
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
1:28
2020 ttf egfr qa panel can a tissue biopsy play a role in disrupting the cancer and cause spread
-
1:59:57
grace - global resource for advancing cancer education live stream
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
1:22:21
egfr breakout video targeted therapies 2017
-
2:00
ceritinib and other second generation alk inhibitors for acquired resistance in alk-positive nsclc